Dr. Nigg’s research focuses on the underlying mechanisms and causes in attention deficit hyperactivity disorder (ADHD) across the lifespan. The primary focus is on cognitive and neuropsychological mechanisms. However, studies of genetics, family dynamics, personality and temperament, environmental toxins, and neuroimaging of ADHD are also ongoing.
Joel Nigg
Director, Division of Psychology
Oregon Health and Science University
From this contributor
Insights for autism from attention deficit hyperactivity disorder
Autism and attention deficit hyperactivity disorder show genetic and neurobiological overlap, which may provide clues to the origin of both disorders, says Joel Nigg.
Insights for autism from attention deficit hyperactivity disorder
Explore more from The Transmitter
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
What neuroscientists want from a new NINDS director
The search is underway for the next director of the U.S. National Institute of Neurological Disorders and Stroke, who will face a range of challenges, neuroscientists say, but will also have an “immense opportunity to do good things.”
What neuroscientists want from a new NINDS director
The search is underway for the next director of the U.S. National Institute of Neurological Disorders and Stroke, who will face a range of challenges, neuroscientists say, but will also have an “immense opportunity to do good things.”